Trials · Topics · Lymphomas

Lymphomas clinical trials

122 Lymphomas trials (Malignant Hematology) summarized for fellows and board review, newest first within each disease. Each summary covers design, results, toxicity and what changed in practice.

Jump to: LBCL · Indolent Lymphomas · cHL · PTCL · PCNSL · CTCL · WM

LBCL (35)

frontMIND trial Lancet 2026
Adding tafasitamab + lenalidomide to R-CHOP significantly improved PFS in newly diagnosed high-risk DLBCL/HGBL (25% reduction in progression/death), with a concordant...
POLARGO trial J Clin Oncol 2026
Adding polatuzumab vedotin to R-GemOx significantly prolonged OS (40% lower risk of death) in transplant-ineligible R/R DLBCL. Pola-R-GemOx provides an accessible...
Tucidinostat + R-CHOP JAMA 2026
Tucidinostat + R-CHOP significantly improved PFS in non-GCB DLBCL, representing the first positive Phase III trial of an HDAC inhibitor in this biomarker-selected...
IELSG37 JCO 2024
DA-EPOCH-R significantly improved 5-year PFS over R-CHOP (82.8% vs 70.4%, HR 0.52) in PMBCL, with substantially less need for consolidation radiotherapy, confirming...
STARGLO Lancet 2024
Glofitamab + GemOx significantly improved OS (12.6-month gain, HR 0.59) and PFS versus R-GemOx in R/R DLBCL, representing a landmark Phase III OS benefit for a...
EPCORE NHL-1 JCO 2023
Epcoritamab achieved a 63.1% ORR and 38.9% CR rate in heavily pretreated R/R LBCL, including prior CAR-T failures, with manageable subcutaneous administration. This...
KEYNOTE-170 Blood 2023
Pembrolizumab demonstrated a 45.3% ORR with durable responses in heavily pretreated R/R PMBCL, establishing PD-1 blockade as an effective and tolerable strategy in...
BELINDA NEJM 2022
BELINDA was a major negative trial - tisa-cel did not improve EFS versus standard salvage + ASCT as second-line therapy in R/R DLBCL. This contrasted sharply with the...
NP30179 NEJM 2022
Glofitamab with step-up dosing achieved a 39.4% CR rate in heavily pretreated R/R DLBCL, with durable responses (77.6% maintained at 12 months) and a manageable CRS...
PILOT Lancet Oncol 2022
Liso-cel demonstrated high response rates (80.3% ORR, 54.1% CR) in transplant-ineligible R/R DLBCL patients, a population historically treated with palliative intent....
POLARIX NEJM 2022
Pola-R-CHP significantly improved PFS over R-CHOP in IPI ≥2 DLBCL - the first regimen to improve upon R-CHOP in a phase III trial - with similar safety. No OS benefit...
TRANSFORM Lancet 2022
Liso-cel demonstrated superior EFS, CR rate, and OS over salvage + ASCT in second-line LBCL, with a favorable toxicity profile (lower Grade ≥3 CRS/ICANS), providing a...
ZUMA-12 Nat Med 2022
Axi-cel as part of first-line therapy was highly effective in high-risk LBCL, achieving a 78% CRR with a manageable safety profile, supporting investigation of CAR...
LOTIS-2 Lancet Oncol 2021
Loncastuximab tesirine achieved a 48.3% ORR in heavily pretreated R/R DLBCL, with durable responses in CR patients. The PBD-based mechanism provides a non-overlapping...
ROBUST JCO 2021
R²-CHOP did not improve PFS or OS in ABC-type DLBCL (HR 0.85, P=.29). Despite the more rigorous Lymph2Cx RNA-based COO assignment, lenalidomide added no efficacy and...
SEXIE JCO 2021
Adding lenalidomide to R-miniCHOP did not improve OS or PFS in very elderly DLBCL patients. The negative result mirrors ROBUST and PHOENIX, reinforcing that R-CHOP...
ZUMA-7: Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma NEJM 2021
Axi-cel as second-line therapy significantly improved EFS over salvage chemoimmunotherapy plus autologous transplant in early-relapsing or primary-refractory large...
GO29365 (Pola-BR) JCO 2020
Pola-BR significantly improved CR rate, PFS, and OS versus BR in transplant-ineligible R/R DLBCL, leading to FDA accelerated approval in 2019. This established...
Inter-B-NHL Ritux 2010 NEJM 2020
Adding rituximab to LMB-based chemotherapy significantly improved both EFS (93.9% vs 82.3%) and OS (95.1% vs 87.3%) in children and adolescents with high-risk mature...
L-MIND Lancet Oncol 2020
Tafasitamab + lenalidomide demonstrated a 57.5% ORR and durable responses (mDOR 43.9 months) in transplant-ineligible R/R DLBCL, supporting FDA approval. The...
TRANSCEND NHL 001 Lancet 2020
Liso-cel produced high response rates with a markedly lower CRS rate (grade ≥3: 2%) compared with other approved CAR-T products in LBCL. The defined CD4:CD8 ratio and...
CALGB 50303 JCO 2019
DA-EPOCH-R did not improve PFS or OS vs R-CHOP in unselected DLBCL, with greater toxicity in the experimental arm. This definitively confirmed R-CHOP as the standard...
FLYER Trial Lancet 2019
In young patients with favorable-prognosis aggressive B-cell lymphoma (stage I-II, normal LDH, <7.5 cm), 4 cycles of R-CHOP plus 2 doses of rituximab is non-inferior...
JULIET NEJM 2019
Tisa-cel produced durable responses in heavily pretreated R/R DLBCL, with a 40% CR rate and 65% sustained responses at 12 months in responders. These results...
PHOENIX JCO 2019
Ibrutinib added to R-CHOP did not improve EFS in non-GCB DLBCL (HR 0.93, P=.43). A post-hoc nominal benefit in younger patients (<60 years) did not meet the...
DA-EPOCH-R (DHL/THL) Lancet Haematol 2018
DA-EPOCH-R achieved durable long-term remissions in DHL/THL - markedly better than historical R-CHOP outcomes - without the toxicity of very intensive induction...
PETAL JCO 2018
PET-guided intensification to a Burkitt-like protocol in PET-positive DLBCL after 2 cycles of R-CHOP did not improve EFS (42% vs. 32%, HR 1.50, P=.12) and caused...
GOYA JCO 2017
Obinutuzumab-CHOP did not improve PFS or OS compared to R-CHOP in untreated DLBCL (HR 0.92, P=.40), with higher infusion-related reaction rates. Obinutuzumab is not...
ZUMA-1 NEJM 2017
Axi-cel produced high response rates in multiply relapsed/refractory LBCL, with ~54% CR and ~31% of patients remaining progression-free at 5 years, supporting...
DA-EPOCH-R (PMBCL) NEJM 2013
DA-EPOCH-R achieved exceptional 5-year EFS (93%) and OS (97%) in PMBCL without routine mediastinal radiotherapy, establishing this as a preferred standard for young...
GELA LNH 03-2B Lancet 2011
R-ACVBP with sequential consolidation significantly improved EFS and OS over R-CHOP in younger high-risk DLBCL, at the cost of substantially greater toxicity....
CORAL JCO 2010
R-ICE and R-DHAP produced equivalent salvage outcomes in R/R DLBCL prior to ASCT. Prior rituximab exposure was the dominant prognostic factor, with a 2-fold increase...
LNH-98.5 (GELA) Blood 2010
R-CHOP significantly improved CR rate, EFS, PFS, and OS compared to CHOP in elderly DLBCL, with 10-year OS improved from 27.6% to 43.5%. This trial established R-CHOP...
RICOVER-60 Lancet Oncol 2008
Addition of rituximab to CHOP-14 significantly improved EFS and OS in elderly DLBCL, establishing R-CHOP-14×6 as a standard of care. Extending treatment to 8 cycles...
MInT trial, CHOP vs R-CHOP Lancet Oncol 2006
Landmark practice-changing trial establishing chemoimmunotherapy (R-CHOP) as standard of care in young good-prognosis DLBCL, with EFS and OS benefit sustained at...

Indolent Lymphomas (32)

EPCORE FL-1 Lancet 2026
Epcoritamab + R² demonstrated a landmark PFS benefit over R² alone (HR 0.21, 2-year PFS 76% vs ~45%) with an 83% CR rate, establishing epcoritamab + R² as the most...
inMIND Lancet 2026
Adding tafasitamab to R² (T+R²) significantly improved PFS versus R² alone in R/R FL (HR 0.43), establishing tafasitamab's activity in FL and representing the first...
RENOIR trial Blood Adv 2026
Adding lenalidomide to rituximab maintenance did not significantly improve 2-yr PFS in elderly R/R FL despite a numerical benefit, with added toxicity. In older...
SWOG S0016 (15-YEAR) JAMA Oncol 2026
Approximately 42% of patients with advanced-stage FL treated with CHOP-based chemoimmunotherapy achieved functional cure, with relapse rates declining markedly after...
SYMPATICO final analysis Br J Haematol 2026
With ~5 years of follow-up, ibrutinib + venetoclax maintained superior PFS, CR rate, and time to next treatment over ibrutinib alone in R/R MCL, including...
TRIANGLE 4.5-year update Lancet 2026
After 4.5 years, adding ASCT to an ibrutinib-containing first-line regimen did not improve failure-free survival and increased toxicity, while both...
SYMPATICO Lancet Oncol 2025
Ibrutinib + venetoclax significantly improved PFS versus ibrutinib alone in R/R MCL (HR 0.65, median PFS 31.9 vs 22.1 months), with markedly higher MRD negativity...
RESORT (E4402) JCO 2024
Rituximab maintenance significantly delayed time to chemotherapy versus retreatment in low-burden FL, but with identical 10-year OS. Maintenance requires...
TRANSCEND FL Nat Med 2024
Liso-cel achieved a 73.4% CR rate and 95.7% ORR in R/R FL with a markedly improved safety profile - grade ≥3 CRS only 1.4% compared to 7% with axi-cel - confirming...
TRIANGLE Lancet 2024
Ibrutinib-containing induction plus maintenance was superior to ASCT alone, and ASCT added no clear benefit when ibrutinib was given. Practice-changing: ASCT can be...
ROSEWOOD JCO 2023
Zanubrutinib + obinutuzumab significantly improved ORR (69% vs 46%) and PFS (HR 0.50) versus obinutuzumab alone in R/R FL, with a favorable safety profile including...
ELARA Nat Med 2022
Tisagenlecleucel achieved high, durable complete responses with a manageable safety profile in heavily pretreated r/r FL, including high-risk POD24 patients...
Mosunetuzumab (FL) Lancet Oncol 2022
Mosunetuzumab achieved a 60% CR rate with 0% grade ≥3 CRS, durable responses (mDOR not reached in CRs), and a fixed 8-cycle treatment duration - establishing the...
SHINE NEJM 2022
Adding ibrutinib to BR prolonged PFS by ~28 months in older untreated MCL, but without OS benefit and with substantially higher toxicity (atrial fibrillation...
WINDOW-1 Lancet Oncol 2022
An ibrutinib window plus chemoimmunotherapy without ASCT achieved exceptional CR rates (89%) and 3-year PFS (86%) in transplant-eligible MCL, establishing this as a...
ZUMA-5 Lancet Oncol 2022
Axi-cel achieved exceptional long-term outcomes in R/R FL - ORR 94%, CR 79%, with a 5-year median PFS of 62.2 months - demonstrating durable remissions and potential...
MAGNOLIA Clin Cancer Res 2021
Zanubrutinib achieved a 68.2% ORR with durable responses (mDOR 55.5 months) in R/R MZL with markedly fewer cardiovascular toxicities (atrial fibrillation 2.9%, no...
Tazemetostat FL Lancet Oncol 2020
Tazemetostat produced clinically meaningful responses in R/R FL, particularly in EZH2-mutant tumors (ORR 69%), with durable responses and an excellent tolerability...
ZUMA-2 NEJM 2020
Brexucabtagene autoleucel achieved 93% ORR with 67% CR in heavily pretreated post-BTKi R/R MCL, establishing the first CAR-T approval in MCL. ICANS rates are higher...
AUGMENT JCO 2019
R² significantly improved PFS in R/R FL (median PFS 39.4 vs 14.1 months, HR 0.46), with an OS benefit emerging at 5-year follow-up (HR 0.59), establishing R² as a...
TROG 99.03 JCO 2019
In early-stage low-grade follicular lymphoma, adding systemic (chemo)immunotherapy to involved-field radiotherapy significantly improved PFS over radiotherapy alone...
RELEVANCE NEJM 2018
R² achieved equivalent 10-year PFS and OS compared to R-chemoimmunotherapy in frontline advanced FL, establishing R² as a validated chemotherapy-free alternative with...
GALLIUM NEJM 2017
Obinutuzumab-chemotherapy significantly improved PFS over rituximab-chemotherapy in untreated FL, but with greater toxicity and no OS benefit, raising questions about...
IELSG-19 JCO 2017
Rituximab + chlorambucil significantly improved 5-year EFS versus either agent alone in extranodal MALT lymphoma, establishing the R+Clb combination as the standard...
PCYC-1121 (Ibrutinib MZL) Blood 2017
Ibrutinib achieved a 58% ORR with durable responses (median DoR 27.6 months) in R/R MZL, establishing BTK inhibition as an effective treatment strategy for this...
GADOLIN Lancet Oncol 2016
Obinutuzumab + bendamustine followed by obinutuzumab maintenance significantly improved PFS and OS versus bendamustine alone in rituximab-refractory indolent NHL...
RAY Lancet 2016
Ibrutinib significantly prolonged PFS and improved ORR compared with temsirolimus in R/R MCL, with a more favorable overall toxicity profile. This trial confirmed...
Ardeshna (Watch-Wait vs Early R) Lancet Oncol 2014
Early rituximab significantly delayed time to next treatment and improved PFS in low-tumor-burden FL but did not improve OS. Results support early rituximab as an...
BRIGHT trial Blood 2014
B-R was non-inferior to R-CHOP/R-CVP for CR with similar ORR; in the 5-year update B-R showed superior PFS (notably in MCL) but no OS advantage, with a distinct...
StiL trial 2013
Bendamustine-rituximab provides superior PFS and a more favorable toxicity profile (less neutropenia, infection, alopecia, neuropathy) versus R-CHOP for first-line...
European MCL Network elderly NEJM 2012
R-CHOP induction followed by rituximab maintenance significantly improved PFS and OS compared with all other arms in elderly MCL. R-FC was inferior due to higher...
PRIMA Lancet 2011
Two years of rituximab maintenance after first-line immunochemotherapy significantly and durably improves PFS in high-tumor-burden follicular lymphoma, without an OS...

cHL (28)

E4412 Blood 2026
Addition of ipilimumab to BV+nivolumab did not significantly improve CR rate overall in R/R cHL, but showed a signal of improved 36-month PFS (73% vs. 46%) in...
EuroNet-PHL-LP1 Blood Adv 2026
Early-stage pediatric nLPHL can be managed with surgery alone (~80% 5-yr EFS) or with low-intensity, anthracycline-free CVP achieving 91% 5-yr PFS when...
H10 (EORTC/LYSA/FIL) JCO 2024
In favorable early-stage cHL (H10F), RT omission in iPET-negative patients resulted in a 13.4 percentage-point deficit in 10-year PFS - the trial arm was stopped...
HD21 (GHSG) Lancet 2024
BrECADD achieved significantly superior 4-year PFS (94.3% vs. 90.9%) and substantially lower treatment-related morbidity compared to eBEACOPP in advanced-stage cHL...
S1826 NEJM 2024
N-AVD significantly improved PFS over A+AVD with a better tolerability profile (less neuropathy, no required G-CSF) in advanced Hodgkin lymphoma, establishing...
KEYNOTE-087 Blood 2023
Pembrolizumab achieved a 71.4% ORR with durable responses in approximately one-quarter of patients at 5 years, supporting its role as an active and manageable therapy...
AHOD1331 NEJM 2022
Addition of brentuximab vedotin to standard ABVE-PC significantly improved 3-year EFS (92.1% vs. 82.5%, HR 0.41) in pediatric high-risk Hodgkin lymphoma, the first...
EuroNet-PHL-C1 Lancet Oncol 2022
EuroNet-PHL-C1 established two European pediatric HL standards: (1) COPDAC is noninferior to COPP for EFS with significantly less gonadotoxicity, replacing...
BV + Nivolumab (R/R cHL) Blood 2021
BV+nivolumab achieved an 85% ORR and 67% CR rate in R/R cHL - substantially higher than either agent alone - with 91% 3-yr PFS in patients bridged to ASCT. Now widely...
HD14 (GHSG) Lancet Haematol 2021
The 2+2 regimen (2×BEACOPPesc + 2×ABVD + IF-RT) significantly improved FFTF compared to 4×ABVD + IF-RT in early-stage unfavorable cHL, with persistent superiority...
HD17 (GHSG) Lancet Oncol 2021
PET4-guided omission of RT after 2+2 induction chemotherapy met noninferiority criteria for 5-year PFS in early-stage unfavorable cHL, representing the first RCT...
KEYNOTE-204 Lancet Oncol 2021
Pembrolizumab significantly improved PFS compared to brentuximab vedotin in R/R cHL (median 13.2 vs. 8.3 months; HR 0.65), establishing pembrolizumab as the preferred...
Pembro-GVD (R/R cHL) JCO 2021
Pembrolizumab plus GVD achieved an extraordinary 95% CR rate and 100% ORR in R/R cHL as second-line salvage therapy, with 95% bridging to AHCT and all transplanted...
NLPHL (GHSG HD7-HD15) JCO 2020
Long-term analysis of 471 NLPHL patients demonstrated 10-year PFS of 75.5% and OS of 92.1%, with IF-RT achieving excellent stage IA outcomes (8-yr PFS 91.9%). The ~8%...
AHL2011 (LYSA) Lancet Oncol 2019
PET-adapted de-escalation (2×BEACOPP escalated → ABVD in PET2-negative patients) maintains 5-year PFS equivalent to 6×BEACOPP escalated with significantly reduced...
AHOD0831 (COG) Br J Haematol 2019
Response-adaptive DECA intensification for SER in high-risk pediatric cHL achieved a 4-year EFS of 69.3% - inferior to RER outcomes (86.6%) despite intensification...
AETHERA Blood 2018
Post-ASCT consolidation with BV significantly reduced the risk of progression (HR 0.52, 5-yr PFS 59% vs. 41%) in high-risk cHL, without a significant OS benefit...
CheckMate 205 JCO 2018
Nivolumab achieved a 69% ORR with durable responses (mDOR 16.6 mo) in heavily pretreated R/R cHL after ASCT - including post-BV patients - supporting FDA approval...
ECHELON-1 NEJM 2018
A+AVD improved modified PFS and, on long-term follow-up, OS versus ABVD in advanced Hodgkin lymphoma while eliminating bleomycin pulmonary toxicity, establishing...
HD18 (GHSG) Lancet 2017
Four cycles of BEACOPPesc was noninferior to eight cycles for PFS in iPET2-negative advanced-stage cHL and associated with improved OS due to fewer treatment-related...
RATHL NEJM 2016
Bleomycin omission in iPET2-negative advanced-stage cHL (de-escalation to AVD) met noninferiority criteria for PFS with significantly lower pulmonary toxicity and no...
HD13 (GHSG) Lancet 2015
Neither bleomycin nor dacarbazine can be safely omitted from ABVD for early-stage favorable cHL - all modified regimens showed inferior FFTF. 2×ABVD + 30 Gy IFRT...
RAPID NEJM 2015
Omission of IF-RT in iPET-negative early-stage cHL failed to meet the prespecified 10-percentage-point noninferiority margin for 3-year PFS, with a 3.8 pp PFS...
AHOD0031 (COG) JCO 2014
RT omission did not achieve pre-specified non-inferiority in intermediate-risk pediatric cHL: the 90% CI crossed the -5% margin. The absolute 3.6% EFS difference...
BV Pivotal (R/R cHL) JCO 2012
BV demonstrated a 75% ORR with 34% CR rate in heavily pretreated R/R cHL after ASCT failure, leading to FDA accelerated approval on August 19, 2011 - the first new...
HD15 (GHSG) Lancet 2012
6×BEACOPP escalated was non-inferior to 8×BEACOPP escalated in FFTF with superior OS, establishing 6×eBEACOPP as the new GHSG standard for advanced cHL. BEACOPP-14...
HD10 (GHSG) NEJM 2010
Two cycles of ABVD plus 20 Gy IF-RT was noninferior to four cycles plus 30 Gy for FFTF and OS, establishing the minimally intensive regimen as the international...
HD11 (GHSG) JCO 2010
4×BEACOPP baseline + 20 Gy IFRT was non-inferior to 4×ABVD + 30 Gy IFRT for early-stage unfavorable HL, establishing that BEACOPP allows reduction of radiation dose....

PTCL (15)

PRIMO JCO 2026
Duvelisib achieved a 48% ORR overall in R/R PTCL, with particularly strong activity in AITL (62.2% ORR, 51.4% CR), among the highest single-agent response rates...
AFM13 (Acimtamig) Clin Cancer Res 2025
Acimtamig demonstrated a 32.4% ORR in heavily pretreated CD30+ R/R PTCL, with the highest activity in AITL (53.3%), and a favorable tolerability profile notable for...
SPIRIT Lancet Haematol 2024
Sintilimab + P-GEMOX achieved 100% ORR and 85.3% CR in newly diagnosed advanced ENKTL, with 2-year PFS 64% and 3-year OS 76%, among the most impressive published...
VALENTINE-PTCL01 Lancet Oncol 2024
Valemetostat achieved a 44% ORR with activity across PTCL subtypes including AITL (52% ORR), establishing dual EZH1/2 inhibition as a clinically active strategy in...
AcSé-Crizotinib (ALK+ ALCL) Eur J Cancer 2023
Crizotinib achieved a 67% ORR (50% CR) with durable responses (median DoR 43.3 months, 3-year OS 63%) in R/R ALK+ sALCL, establishing ALK inhibition as a highly...
ANHL12P1 JCO 2023
Crizotinib + chemotherapy achieved a 2-year EFS of 76.8% in pediatric ALK+ ALCL, substantially better than historical ALCL99 results (~50% EFS). However...
CC-486+CHOP (TFH/AITL) Blood 2023
CC-486 + CHOP achieved exceptionally high CR rates (88.2%) in TFH-phenotype PTCL, particularly in TET2-mutated AITL (100% CR). This provides strong proof-of-concept...
DDGP vs SMILE JAMA Oncol 2022
DDGP significantly outperformed SMILE in advanced ENKTL (ORR 90% vs 60%, CR 72.5% vs 37.5%, median PFS not reached vs 6.8 months, 3-year OS 68% vs 41%) with markedly...
Ro-CHOP JCO 2022
Adding romidepsin to CHOP failed to improve PFS in unselected PTCL (HR 0.79, P=.054), while substantially increasing hematologic toxicity. An exploratory subgroup...
ECHELON-2 Lancet 2019
A+CHP significantly improved PFS and OS over CHOP in CD30+ PTCL - the first phase III regimen to show an OS benefit in this setting - establishing A+CHP as standard...
BELIEF JCO 2015
Belinostat achieved a 25.8% ORR with a favorable hematologic toxicity profile, notably lower thrombocytopenia (7%) and neutropenia (11%) than other approved PTCL...
BV Monotherapy (sALCL) JCO 2012
Brentuximab vedotin achieved an 86% ORR (57% CR) in R/R sALCL with remarkable durability, with no progressions beyond 40 months in CR patients, suggesting potential...
Mogamulizumab (ATLL) JCO 2012
Mogamulizumab achieved a 50% ORR (31% CR) in heavily pretreated R/R ATLL with some durable responses, establishing CCR4 targeting as an effective strategy in this...
Romidepsin (PTCL) JCO 2012
Romidepsin achieved a 25% ORR (15% CR/CRu) with durable responses (median DoR 17 months) in R/R PTCL, with some long-term remissions beyond 34 months, establishing it...
PROPEL JCO 2011
Pralatrexate achieved a 29% ORR with a 10.1-month mDOR in heavily pretreated R/R PTCL - modest efficacy but durable responses in a subset - leading to FDA accelerated...

PCNSL (6)

MATRix/IELSG43 trial Lancet 2026
In the largest randomized trial in untreated PCNSL to date, thiotepa-based HCT-ASCT significantly improved progression-free and overall survival versus...
PRECIS JCO 2019
ASCT consolidation significantly improved 2-year PFS (87% vs 63%, HR 0.52) compared to WBRT in patients aged ≤60 years with PCNSL in response after HD-MTX-based...
IELSG-32 (Consolidation) Lancet Haematol 2017
In PCNSL patients responding to MATRix induction, ASCT and WBRT consolidation both produced high 2-year PFS and OS with no significant survival difference, but ASCT...
IELSG-32 (Induction) Lancet Haematol 2016
MATRix (MTX + cytarabine + thiotepa + rituximab) achieved the highest CR rate (49%) and best 2-year OS among the three induction regimens in newly diagnosed PCNSL...
ANOCEF-GOELAMS Elderly Lancet Haematol 2015
MT and MPVA showed numerically different but statistically non-significant EFS and OS in elderly PCNSL, with MPVA producing higher toxicity; neither matched outcomes...
CALGB 50202 JCO 2013
MT-R induction followed by EA consolidation achieved a 2-year PFS of 57% and preserved neurocognitive function without whole-brain radiotherapy in newly diagnosed...

CTCL (4)

MAVORIC Lancet Oncol 2018
Mogamulizumab significantly improved PFS and ORR versus vorinostat in R/R MF and Sézary syndrome, with particularly pronounced benefit in SS (mPFS 15.1 vs 3.5 months...
ALCANZA Lancet 2017
Brentuximab vedotin significantly improved ORR≥4 months and PFS versus physician's choice in CD30+ MF and pcALCL, with a more than 4-fold improvement in the primary...
Romidepsin CTCL JCO 2010
Romidepsin achieved a 34% ORR with 6% CR in refractory CTCL, with a clinically meaningful median response duration of 15 months. Pruritus relief was observed in 43%...
Vorinostat CTCL JCO 2007
Vorinostat achieved a 29.7% ORR with durable responses (estimated DOR ≥185 days) and meaningful pruritus relief in treatment-refractory MF/SS. The oral formulation...

WM (2)

ASPEN Blood 2020
Zanubrutinib did not meet the primary endpoint of superior ≥VGPR rate in MYD88 L265P WM (P=.09), but demonstrated a markedly lower rate of atrial fibrillation (2.5%...
iNNOVATE NEJM 2018
Ibrutinib + rituximab significantly improved PFS and response rates vs placebo + rituximab in WM, preventing the rituximab-associated IgM flare and establishing BTK...